Alecta Tjanstepension Omsesidigt Increases Stock Holdings in Insulet Corporation $PODD

Key Points

• Alecta Tjanstepension Omsesidigt increased its stake in Insulet Corporation by 30.2%, owning 265,300 shares valued at approximately $83.3 million at the end of the second quarter.
• Insulet's quarterly earnings surpassed expectations, reporting $1.17 earnings per share against an estimate of $0.92, with revenue of $649.1 million reflecting a 32.9% year-over-year increase.
• Analysts remain optimistic about Insulet, with a consensus rating of "Moderate Buy" and price targets raised, including Piper Sandler's target increase to $360.00.

Alecta Tjanstepension Omsesidigt increased its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 30.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 265,300 shares of the medical instruments supplier's stock after purchasing an additional 61,500 shares during the period. Alecta Tjanstepension Omsesidigt owned approximately 0.38% of Insulet worth $83,331,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of PODD. Janus Henderson Group PLC increased its position in shares of Insulet by 7.0% in the fourth quarter. Janus Henderson Group PLC now owns 7,846 shares of the medical instruments supplier's stock worth $2,049,000 after purchasing an additional 511 shares during the period. ProShare Advisors LLC increased its position in shares of Insulet by 12.3% in the fourth quarter. ProShare Advisors LLC now owns 10,614 shares of the medical instruments supplier's stock worth $2,771,000 after purchasing an additional 1,159 shares during the period. Toronto Dominion Bank increased its position in shares of Insulet by 55.2% in the fourth quarter. Toronto Dominion Bank now owns 36,486 shares of the medical instruments supplier's stock worth $9,526,000 after purchasing an additional 12,984 shares during the period. Tidal Investments LLC increased its position in shares of Insulet by 9.8% in the fourth quarter. Tidal Investments LLC now owns 10,283 shares of the medical instruments supplier's stock worth $2,685,000 after purchasing an additional 918 shares during the period. Finally, Cornerstone Advisory LLC bought a new position in shares of Insulet in the fourth quarter worth $238,000.

Analyst Ratings Changes

A number of brokerages recently commented on PODD. Royal Bank Of Canada raised their price target on Insulet from $330.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. JPMorgan Chase & Co. raised their price objective on Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a research note on Friday, September 12th. Canaccord Genuity Group raised their price objective on Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Truist Financial began coverage on Insulet in a research note on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective on the stock. Finally, Oppenheimer raised their price objective on Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research note on Monday, September 8th. Sixteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $343.06.

Insulet Trading Down 0.8%

Insulet stock traded down $2.67 during trading hours on Friday, hitting $330.84. The stock had a trading volume of 1,028,492 shares, compared to its average volume of 567,226. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $23.29 billion, a price-to-earnings ratio of 100.56, a P/E/G ratio of 2.77 and a beta of 1.36. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50. The business's 50 day simple moving average is $315.14 and its 200-day simple moving average is $294.10.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm's revenue was up 32.9% compared to the same quarter last year. During the same period last year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, SVP Prem Singh sold 687 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.